US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results

US$7.83 - That's What Analysts Think Akebia Therapeutics, Inc. (NASDAQ:AKBA) Is Worth After These Results
Akebia Therapeutics' stock price rose 19% to US$2.26 after announcing revenues of US$160m, above expectations, but recorded a loss of US$0.33. Analysts forecast a 21% increase in revenue to US$193.